



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Ain Shams University

Faculty of Pharmacy

Department of Pharmacology and Toxicology

Study on potential protective effect of acetaminophen in experimentally induced Parkinson's disease in rats

A thesis submitted for the partial fulfillment of requirements for the Master degree in
Pharmaceutical Sciences
(Pharmacology & Toxicology)

By

Aya Yassin Mohamed Mahmoud

B.Pharm. Sc., Ain Shams University (2014)

Demonstrator of Pharmacology and Toxicology

Faculty of Pharmacy, Heliopolis University.

Under the supervision of:

Marian George Tadros, Ph.D.

Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University.

Reem Nabil Abou El-Naga, Ph.D.

Associate Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University.

Al-Shaimaa Amin Zaki El-Bahy, Ph.D.

Lecturer in Pharmacology and Toxicology Department, Faculty of Pharmaceutical Sciences, University of Hertfordshire.

Faculty of Pharmacy-Ain Shams University

2021

Acknowledgments

Acknowledgements can never be made to all those who have nourished my intellectual life. However, I must try to give credit where credit is due.

Above all, utmost appreciation and gratitude is to the Almighty Allah for the divine intervention in the academic endeavor.

I am greatly thankful to my great professor and thesis advisor, Prof. Dr. Marian George Tadros, Professor of Pharmacology and toxicology, Faculty of Pharmacy, Ain Shams University, for her indispensable help throughout the whole thesis work as well as her unwavering guidance, continuous support and positive insights.

I am also greatly thankful to Associate Prof. Reem Nabil Abou El-Naga, Associate Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for her significant help throughout the whole Thesis work as well as her continuous guidance, and support.

I would like to thank Dr. Al-Shaimaa Amin Zaki El-Bahy, Lecturer of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Hertfordshire, for her help and support throughout the whole thesis work.

I also express my deep gratitude to Dr. Haidy Effat, lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for her great effort and aid in practical work, statistical analysis, and scientific writing.

I would like to thank Dr. Ramy Ammar, Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Kafr El-Sheikh University, for his great effort and aid in the experimental design.

Finally, I would like to express my deep gratefulness and thanks to my husband and my family for their continuous moral and emotional support.

List of contents

Introduction.....	1
I. Parkinson's Disease	1
I-1. Overview	1
I-2. Epidemiology	2
I-2.1. Prevalence and mortality	2
I-2.4. Parkinson's disease in Egypt	3
I-3. The pathogenesis of Parkinson's disease.....	4
I-3.1. Oxidative stress in Parkinson's disease	6
I-3.2. Inflammation in Parkinson's disease	9
I-3.3. Apoptosis in Parkinson's disease.....	11
I-4. Diagnosis of Parkinson's disease	12
I-5. Management of Parkinson's disease.....	15
I-5.1. Non-pharmacological management	15
I-5.2. Pharmacological management	16
I-7. Concluding remarks:.....	22
II. Animal models of Parkinson's disease	23
II-1. 6-hydroxy dopamine (6-OHDA)	25
II-2. 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP):	26
II-3. Rotenone:	27
III-Acetaminophen	30
III-1. History:	30
III-2. Pharmacokinetics of acetaminophen:.....	32
III-3. Pharmacodynamics	34
III-3.1. Acetaminophen and the Endocannabinoid system.....	34

II-3.2. CNS-related actions:.....	35
II-3.3. Non-CNS-related actions:	38
II-5. Concluding remarks:	40
Aim of the work.....	41
Material and methods.....	42
I- Experimental design	42
I-1. Dose-Response Study	42
I-2. The Mechanistic Study	43
II- Animals	46
III- Material	46
III-1. Drugs:.....	46
III-2. Chemicals and reagents:	47
III-3. Antibodies:.....	48
III-4. Kits:.....	49
III-5. Apparatuses:.....	49
IV- Methods	51
IV-1. Behavioral tests:.....	51
IV-1.1. Spontaneous locomotor activity:	51
IV-1.2. Rotarod test:.....	51
IV-2. Biochemical assessment of oxidative stress markers:	52
IV-2.1. Malondialdehyde (MDA):	52
IV-2.2. Reduced glutathione (GSH):.....	53
IV-3. Assessment of DA content in the striatum:	55
IV-4. Midbrain and striatal Cytochrome-C quantification.....	56
IV-5. Assessment of caspase-3 activity in midbrain and striatum	60

IV-6. Determination of CB1 and CB2 receptors mRNA expression in midbrain and striatum:.....	65
IV-7. Histological examination:	70
IV-8. Immunohistochemistry:	70
IV-9. Statistical analysis.....	73
Results.....	75
I- The dose-response study:.....	74
I-1. The effects of ACM on locomotor activity of rotenone-treated rats	74
I-2. The Effects of ACM on the rotarod performance of rotenone-treated rats.....	77
I-3. The effects of ACM on Histological Structure of the Midbrain and striatum	80
I-4. The effects of ACM on TH Immunoreactivity	83
I-5. The effects of ACM on α -synuclein Immunoreactivity	87
I-6. The effects of ACM on striatal DA content.....	92
II-The Mechanistic study:	96
II-1. The effects of ACM and URB597 on rotenone-induced neuro-inflammation:.....	96
II-1.1. The effects of ACM and URB597 on NF-KB immunoreactivity:.....	96
II-1.2. The effects of ACM and URB597 on COX-2 immunoreactivity:.....	101
II-1.3. The effects of ACM and URB597 on iNOS immunoreactivity:	106
II-2. The effects of ACM and URB597 on rotenone-induced oxidative stress	111
II-2.1. Effects of ACM and URB597 on MDA levels.....	111
II-2.2. The effects of ACM and URB597 on GSH levels:	114
II-3. The effects of ACM and URB597 on rotenone-induced apoptosis.....	117
II-3.1. The effects of ACM and URB597 on caspase-3 activity:	117
II-3.2. The effects of ACM and URB597 on cytochrome-c levels	120
II-4. The effects of ACM and URB597 on rotenone-induced change in ECB receptors' expression.....	123
II-4.1. The effects of ACM and URB597 on CB1 receptor mRNA expression.....	123

II-4.2. The effects of ACM and URB597 on CB2 receptor mRNA expression.....	126
Discussion.....	129
Summary and conclusions.....	140
References.....	148
Arabic summary.....	

List of abbreviations

5-HT	5-hydroxytryptamine
6-OHDA	6-hydroxydopamine
A%	Area percentage
AADC	Aromatic L-amino acid decarboxylase
Ac-DEVD-pNA	Acetyl-Asp-Glu-Val-Asp p-nitroanilide
ACh	Acetylcholine
ACM	Acetaminophen
AM404	N-arachidonoylphenolamine
ANOVA	Analysis of variance
BBB	Blood brain barrier
BDNF	Brain-derived neurotrophic factor
BSA	Bovine serum albumin
CB1	Cannabinoid receptor type 1
CB2	Cannabinoid receptor type2
CCH	Chronic cerebral hypoperfusion
cDNA	Complementary DNA
COX-2	Cyclooxygenase 2
CSF	Cerebrospinal fluid
DA	Dopamine
DAT	Dopamine transporter
DMSO	Dimethylsulphoxide
DTNB	5,5'-dithio-bis-(2-nitrobenzoic acid)
ECB	Endocannabinoid
ECD	Electrochemical detector
FAAH	Fatty acid amide hydrolase
GPI	Globus pallidus interna

GSH	Reduced glutathione
NP-SH	Non-protein thiol
GSH-Px	Glutathione peroxidase
H&E	Hematoxyline and eosine
H ₂ O ₂	Hydrogen peroxide
HPLC	High performance liquid chromatography
HRP	Horseradish peroxidase
IFN- γ	Interferon- γ
IHC	Immunohistochemistry
IL-1 β	Interleukin-1 β
iNOS	Inducible nitric oxide synthase
LB	Lewy bodies
L-dopa	Levodopa
LID	Levodopa-induced dyskinesia
MAO	Monoamine oxidase
MAPK	Mitogen-activated protein kinases
MDS	Movement disorder society
MMLV-RT	Moloney Murine Leukemia Virus reverse transcriptase
MOMP	Mitochondrial outer membrane permeabilization
MPDP ⁺	1-methyl-4-phenyl-2,3-dihydropyridinium
MPP ⁺	1- methyl-4-phenylpyridinium
MPTP	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine
MRI	Magnetic resonance imaging
NAC	N-acetyl cysteine
NAPQI	<i>N</i> -acetyl- <i>p</i> -benzoquinone imine
NF- κ B	Nuclear factor kappa-light chain-enhancer of activated B cells
NMDA	N-methyl-D-aspartate

NO	Nitric oxide
NSAIDs	Non-steroidal anti-inflammatory drugs
OD	Optical density
<i>p</i> value	Probability value
PBS	Phosphate buffered saline
PD	Parkinson's disease
PET	Positron emission tomography
PGs	Prostaglandins
PI3K	Phosphoinositide 3-kinase
pNA	P-nitroaniline
qPCR	Quantitative PCR
ROS	Reactive oxygen species
RQ	Relative quantification
RT-PCR	Real time polymerase chain reaction
SEM	Standard error of mean
SN	Substantia nigra
SNpc	Substantia nigra pars compacta
SOD	Super oxide dismutase
STZ	Streptozotocin
TCA	Trichloroacetic acid
TH	Tyrosine hydroxylase
TMB	Tetramethylbenzidine
TNF- α	Tumor necrosis factor- α
TRPV1	Transient receptor potential vanilloid type 1
UPS	Ubiquitin proteasome system
URB597	Cyclohexylcarbamic acid 3'-(Aminocarbonyl)-[1,1'-biphenyl]-3-yl ester
VMAT-2	Vesicular monoamine transporter-2

List of figures

Figure number	Figure title	Page
i	Pathophysiology of PD	5
ii	DA oxidation to form neuromelanine	8
iii	Summary of pharmacological treatments of PD targeting the dopaminergic pathway	19
iv	Neurotoxin-based PD models; 6-OHDA, MPTP, and rotenone	24
v	Chemical structure of acetanilide, acetaminophen and phenaceti	31
vi	Two-step metabolism of ACM to form AM404	35
1	Schematic diagram illustrating study design	45
2	The standard curve of cytochrome-C	59
3	The standard calibration curve of caspase-3	64
4	The effects of different doses of ACM on rotenone-induced locomotor activity changes in rats	76
5	Effects of different doses of ACM on rotenone-induced changes in latency of rats to fall off the rotarod	79
6 (A-E)	Representative photomicrographs of H&E-stained rats' midbrain areas	81
7 (A-E)	Representative photomicrographs of H&E-stained rats' striatal areas	82
8 (A-E)	Representative photomicrographs of immunohistochemical staining of midbrain TH.	84
9	Quantitative image analysis for immunohistochemical examination of TH.	86
10 (A-E)	Representative photomicrographs of immunohistochemical staining of midbrain α -synuclein	88
11 (A-E)	Representative photomicrographs of immunohistochemical staining of striatal α -synuclein.	89
12	Quantitative image analysis for immunohistochemical examination of α -synuclein in midbrain and striatum.	91

13	The effects of ACM on striatal DA levels in rotenone-treated rats.	94
14 (A-F)	Photomicrographs of immunohistochemical staining of NF- κ B expression in midbrain areas.	97
15 (A-F)	Photomicrographs of immunohistochemical staining of NF- κ B expression in midbrain areas.	98
16	Quantitative image analysis for immunohistochemical examination of NF-KB in midbrain and striatum	100
17	Photomicrographs of immunohistochemical staining of COX-2 expression in midbrain areas	102
18	Photomicrographs of immunohistochemical staining of COX-2 expression in striatal areas.	103
19	Quantitative image analysis for immunohistochemical examination of COX-2 in midbrain and striatum	105
20	Photomicrographs of immunohistochemical staining of iNOS expression in midbrain areas.	107
21	Photomicrographs of immunohistochemical staining of iNOS expression in striatal areas.	108
22	Quantitative image analysis for immunohistochemical examination of iNOS in midbrain and striatum.	110
23	The effects of ACM and URB597 on rotenone-induced changes in MDA levels.	113
24	The Effects of ACM and URB597 on rotenone-induced changes in GSH levels.	116
25	The effects of ACM and URB597 on rotenone-induced changes in caspase-3 activity	119
26	The effects of ACM and URB597 on rotenone-induced changes in cytochrome-c levels.	122
27	The effects of ACM and URB597 on rotenone-induced changes in CB1 receptor mRNA expression.	125
28	The effects of ACM and URB597 on rotenone-induced changes in CB2 receptor mRNA expression.	128
29	Summary of neuroprotective effects of ACM in a rotenone-induced rat model of PD	148

List of tables

Table number	Table title	Page
1	The effects of different doses of ACM on locomotor activity of rotenone-treated rats	75
2	The effects of different doses of ACM on the rotarod performance of rotenone-treated rats	78
3	The effects of different doses of ACM on TH Immunoreactivity in the midbrains of rotenone-treated rats	85
4	The effects of different doses of ACM on α -synuclein immunoreactivity in the midbrains and striata of rotenone-treated rats	90
5	The Effects of different doses of ACM on striatal DA content of rotenone-treated rats	93
6	Effects of ACM and URB597 on NF- κ B immunoreactivity in the midbrains and striata of rotenone-treated rats	99
7	The effects of ACM and URB597 on COX-2 immunoreactivity in the midbrains and striata of rotenone-treated rats	104
8	The effects of ACM and URB597 on iNOS immunoreactivity in the midbrains and striata of rotenone-treated rats	109
9	The effects of ACM and URB597 on MDA levels in the midbrains and striata of rotenone-treated rats	112
10	The effects of ACM and URB597 on GSH levels in the midbrains and striata of rotenone-treated rats	115
11	The effects of ACM and URB597 on caspase-3 activity in the midbrains and striatum of rotenone-treated rats	118
12	The effects of ACM and URB597 on cytochrome-c levels in the midbrains and striata of rotenone-treated rats	121
13	The effects of ACM and URB597 on CB1 receptor mRNA expression in the midbrains and striata of rotenone-treated rats	124
14	The effects of ACM and URB597 on CB2 receptor mRNA expression in the midbrains and striata of rotenone-treated rats	127